|1.||Guo, Chao: 3 articles (02/2015 - 01/2013)|
|2.||Guan, Yue: 3 articles (02/2015 - 01/2013)|
|3.||Wei, Guo: 3 articles (02/2015 - 01/2013)|
|4.||Yin, Ying: 3 articles (02/2015 - 01/2013)|
|5.||Lu, Yin: 3 articles (09/2014 - 09/2010)|
|6.||Fu, Fenghua: 3 articles (04/2012 - 10/2010)|
|7.||Zhang, Leiming: 3 articles (04/2012 - 10/2010)|
|8.||Wang, Tian: 3 articles (04/2012 - 10/2010)|
|9.||Li, Wei: 2 articles (08/2015 - 07/2015)|
|10.||Wang, Yuqiang: 2 articles (07/2015 - 01/2015)|
|1.||Cardiovascular Diseases (Cardiovascular Disease)
08/01/2015 - "Danshensu, as the effective component of Salvia miltiorrhiza (Danshen), has been widely used in clinical studies for treatment of cardiovascular diseases in China. "
01/01/2014 - "Danshensu, the effective ingredient of the plant Salvia miltiorrhiza (Danshen), has been widely used for treatment of cardiovascular diseases. "
01/15/2013 - "Danshensu, as the effective component of Salvia miltiorrhiza (Danshen), has been widely used in clinic for treatment of cardiovascular diseases in China. "
01/01/2015 - "Danshen has been widely used in the treatment of cardiovascular diseases while Danshensu [3(3,4dihydroxyphenyl) 2 hydroxy propanoic acid, DSS], a major water-soluble component of Danshen has also been explored as an important compound in Danshen. "
09/01/2009 - "Danshensu (3-(3,4-dihydroxyphenyl) lactic acid), a natural phenolic acid, is isolated from root of Salvia miltiorrhiza, and is widely used as a traditional Chinese medicine for treatment of various cardiovascular diseases. "
|2.||Brain Ischemia (Cerebral Ischemia)
07/01/2014 - "This indicated that Danshensu could stay longer in cerebral ischemia-reperfusion rats than in normal rats and eliminated more slowly, which reflected the rationality of Danshensu in the clinical treatment of cerebral ischemia diseases. "
07/01/2014 - "[Study on pharmacokinetics-pharmacodynamics correlation of Danshensu in rats with focal cerebral ischemia]."
03/01/2012 - "In the present study, the effects of cerebral ischemia/reperfusion on the transport of Danshensu in the brain were observed by assaying the concentration at 15, 30 and 60 min after cerebral ischemia/reperfusion in the brain of rats. "
07/01/2014 - "According to the results, the pharmacokinetic processes of Danshensu in the cerebral ischemia-reperfusion and normal rats were consistent to the two-compartment model. "
07/01/2014 - "6 software was used to process the data, analyze their correlation, compare the pharmacokinetic difference between model and normal rats after the administration of the same doses of Danshensu and the changes in pharmacodynamic indicators of model rats after the administration, and evaluate the effect of Danshensu in treating the cerebral ischemia disease. "
06/01/2010 - "Protective effects of emodin combined with danshensu on experimental severe acute pancreatitis."
06/01/2010 - "In the present experiment, we aimed to determine the feasibility and curative effects of emodin combined with danshensu on experimental severe acute pancreatitis (SAP) and the mutual benefit of this synergistic strategy by a prospective animal study. "
04/05/2010 - "Danshensu has proven to be effective and safe in ameliorating the prognosis of maternal syndrome in a preeclampsia mouse model. "
01/01/2011 - "We suggest long-term provision of low-dose danshensu in pregnancy, leading to an improvement of preeclampsia syndrome with considerable maternal safety."
01/01/2011 - "Favorable maternal and fetal effects of danshensu in an experimental mice model of preeclampsia."
04/05/2010 - "We suggest long-term provision of low-dose Danshensu in pregnancy, leading to an improvement of preeclampsia syndrome with considerable maternal safety."
04/05/2010 - "Effects of Danshensu on maternal syndrome in phosphatidylserine/phosphatidylcholine microvesicle induced-mouse model: is it a candidate for preeclampsia remedy?"
01/01/2014 - "In addition, danshensu did not induce gastric lesions and even had protective effects on aspirin-induced ulcer formation at doses as high as 60 mg/kg. These findings suggest that the antithrombotic and antiplatelet aggregation effects of danshensu are attributed to its highly selective inhibition of COX-2 and ability to normalize the thromboxane A2(TXA2)/prostacyclin(PGI2) balance. "
|2.||Aspirin (Acetylsalicylic Acid)
|3.||salvianolic acid B
|5.||Thromboxane A2 (A2, Thromboxane)
|1.||Chinese Traditional Medicine (Traditional Chinese Medicine)